this is Pavas Mehra we are present here
at Pareto Securities' annual health
care conference in Stockholm and with me
today I have the CEO of RLS Global
Karin Fischer thank you very
much
could you please tell us a little bit
more about RLS Global and the product
that you're working with yes
RLS Global is a company that has
its history within the dental field we
have actually two products within
caries and periodontitis and these
technology is based on a buffered hypo
chloride and what it does is devitalize the 
 necrotic tissue keeps the healthy tissue
intact and creates an antimicrobial
environment and this is very essential
for an efficient healing process five
years ago there was a doctor that
thought well this must be applicable for
chronicle wound and that's when the
journey started so in April this year we
get our first product approved
CE- approved is a class three device for the
European market and we have initiated
the registration process for Australia
so we hope we can start to launch in
Australia by q2 next year and we are in
dialogue with FDA when it comes to the
US market alright so basically you're
working with wounds that arise in
connection with especially diabetic
patients and there are 16 million
patients that are affected by this annually
how is the market are those 16 million
patients globally or is this only for
the European market that you have
CE-approved now no that's globally those
patients yes and today we have about 425
425 million people suffering in diabetes
and this market if we can use that
working is increasing with somewhere in
between 8 and 10 percent on an annual
basis so if it continues like this we
will be like 650 million people with
diabetes in 25 years and 35
percent of those patients they will
develop at least one a chronical wound
diabetic foot ulcer during their
lifetime
and looking forward out of an investor
perspective you mentioned that you got
the CA approval earlier this year in
April and you are looking to apply for
Australian also an FDA registration
going forward are there any specific
events like timewise the
investors can be on the lookout for well
you know what I mean we are in this very
exciting process right now because we
are in the commlisation process we are
we are we are
I mean how should we actually capture
the market how should we penetrate the
market as fast as possible our business
model is that for the Nordic countries
we have already started and we have our
own sales force taking care of that
market and so far we are doing pretty
well and then we are aiming to sign a
global partnership with a partner who
has a global presence for the rest of the
world but you know when you take a new
product to the market you have to do
this step by step so Europe is our focus
we will do this country by country
secure the reimbursement and then you
know within the next three to four years
I hope that ChloraSolv I know the ChloraSolv
will be present in many regions that
certainly sounds fantastic
we're looking forward forward to
following our list Global ahead thank
you for being here today thank you
